The combination of monoclonal antibodies targeting PD-L1 (programmed death-ligand 1) (atezolizumab) and VEGF (vascular endothelial growth factor) (bevacizumab) represents the new first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC).1 The gene discussed is VEGFA; the disease is hepatocellular carcinoma.